Spinogenix’s Daily Pill SPG302 Receives FDA IND Nod for ALS Treatment
ALS ONE Research Symposium – Presentation by Peter Vanderklish, PhD of Spinogenix
Spinogenix Lands $4M in New Federal Grants
Spinogenix awarded $1M to advance clinical testing of SPG302
Clinical trial of oral ALS therapy SPG302 is enrolling in Australia | ALS News Today
